Sleep Apnea and Stroke
Sleep apnea is common after a stroke and is an independent risk factor for having one. A registry study found CPAP associated with better survival afterwards — and no reduction in recurrence.
Two separate relationships sit inside this question, and they need different answers.
Before a stroke, sleep apnea is a risk factor. After one, sleep-disordered breathing is extremely common — a large fraction of stroke survivors have it — and the question becomes whether treating it changes what happens next.
Why apnea raises stroke risk
The mechanisms are the same ones behind apnea's other cardiovascular associations, and they compound.
Blood pressure. Sleep-disordered breathing predicts new hypertension in a dose-response relationship, and hypertension is the single largest modifiable risk factor for stroke. That chain is well established at both links. Snoring and blood pressure.
Overnight pressure surges and loss of the nocturnal dip, which is itself associated with cerebrovascular risk.
Atrial fibrillation, which apnea is associated with and which is a major cause of embolic stroke. Sleep apnea and atrial fibrillation.
Intermittent hypoxia, driving oxidative stress, inflammation and endothelial dysfunction — and the depth and duration of desaturation appears to matter more than the raw event count. What hypoxic burden measures.
This is why untreated apnea appears in large cohorts alongside cardiovascular events and increased mortality. What untreated apnea does.
After a stroke: what treatment does
A registry-based study followed post-stroke and post-TIA patients with sleep-disordered breathing, comparing those who used CPAP against those who did not (Journal of Stroke and Cerebrovascular Diseases, 2025).
CPAP use was associated with improved survival: hazard ratio 0.75 (95% CI, 0.60–0.92; p = 0.007), and the effect persisted after adjusting for age, sex and pre-existing comorbidities using an updated Charlson Comorbidity Index [J Stroke Cerebrovasc Dis 2025].
But there was no difference in recurrence of stroke or TIA among the CPAP groups across five years of follow-up [ibid].
The authors' conclusion is exactly that split: CPAP was associated with a reduction in all-cause mortality in post-stroke and post-TIA patients with sleep-disordered breathing, and did not appear to affect the risk of another stroke or TIA [ibid].
How to read that
The two halves genuinely pull in different directions, and both belong in the summary.
A 25% relative reduction in mortality is substantial if it is real. Survival after stroke depends on a great deal beyond the cerebrovascular system — cardiac events, aspiration and pneumonia, deconditioning, general resilience — and apnea plausibly touches several of those. A mortality benefit without a recurrence benefit is mechanistically coherent rather than contradictory.
But this is registry data, not a trial. Which means the most important caveat is selection: in a post-stroke population, the patients who obtain and keep using a CPAP machine differ systematically from those who do not. They are likely to have less severe deficits, better cognition, more support at home, and better adherence to everything else. Every one of those independently predicts survival.
That is not a reason to dismiss the finding. It is a reason to hold it as an association, and it is the same pattern seen across CPAP's cardiovascular evidence — strong observational signal, weaker or absent trial confirmation. Does CPAP reduce cardiovascular risk.
Tier 2. How we grade evidence.
Why screening after stroke still matters
Here is the thing the evidence uncertainty does not touch.
Sleep-disordered breathing after stroke is very common and routinely missed, and several of its consequences are immediate rather than long-term. Untreated apnea worsens daytime sleepiness and cognition — both of which bear directly on engagement with rehabilitation, which is when recovery is won or lost.
So the case for identifying and treating it after a stroke does not rest on the recurrence question at all. It rests on sleep quality, daytime function and capacity to participate in rehab, plus blood pressure control, which is the actual lever on recurrence.
Practical notes for anyone in this position:
The presentation can be atypical. Post-stroke apnea may be central rather than obstructive, or a mixture, depending on where the stroke was — and central apnea does not respond to pressure the same way. Central sleep apnea.
Positioning may be constrained. Hemiparesis can make side sleeping difficult, which matters if apnea is positional. Positional therapy.
Mask tolerance can be harder with facial weakness, swallowing difficulty or communication problems, so early specialist input on fit is worth requesting rather than waiting for failure. Getting used to CPAP.
If you have not had a stroke
The useful framing is that apnea is one modifiable contributor among several, and the others are better evidenced: blood pressure control, atrial fibrillation management, smoking, and physical activity.
Treating apnea is worth doing on its own merits — sleepiness, function, quality of life — and any cerebrovascular benefit is a plausible bonus rather than the established reason. Claiming CPAP prevents strokes goes beyond what the evidence supports. What happens after a diagnosis · Risk check.
The line
No consumer product treats obstructive sleep apnea or reduces stroke risk from it. In a stroke survivor, using tape or a strip to quieten snoring instead of getting the breathing assessed is the version of this mistake with the highest stakes. Snoring versus sleep apnea.